Latest progress

Recently, SAL0120 tablet (project code: SAL0120), an innovative small molecule independently developed by Salubris, has been approved by NMPA to carry out clinical trial for the treatment of chronic kidney disease(CKD). 

SAL0120 is a small molecule ETA receptor antagonist independently developed by Salubris, which is intended to be developed for indications including CKD, IgA nephropathy and hypertension, etc. Currently, Phase Ⅱ clinical trial for hypertension is well underway.

If SAL0120 was successfully developed and approved for marketing, it would provide new options for patients with hypertension and kidney disease, meet unmet clinical needs, further enrich the company's innovative product pipeline in the field of chronic disease, and therefore enhancing the company's core competitiveness.